N-(3,5-difluorophenylacetyl)-L-alanyl-L-phenylglycine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3,5-difluorophenylacetyl)-L-alanyl-L-phenylglycine
• 英文别名: N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine；2-(N-[(2S)-2-[[2-(3,5-difluorophenyl)acetyl]amino]propanoyl]anilino)acetic acid
• 化学式: C₁₉H₁₈F₂N₂O₄
• 分子量: 376.36
• InChiKey: YMLCXDMFSUKMTK-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(3,5-difluorophenylacetyl)-L-alanyl-L-phenylglycine 在 二甲胺 作用下， 生成 N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide
  参考文献：
  名称：

  Compounds for inhibiting &bgr;-amyloid peptide release and/or its synthesis

  摘要：

  揭示了一些抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还揭示了包括抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物。

  公开号：

  US06207710B1

文献信息

• Compounds for inhibiting &bgr;-amyloid peptide release and/or its synthesis
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06211235B1

  公开（公告）日：2001-04-03

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis.

  揭示了一种抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还揭示了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物。
• Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide
  申请人：——

  公开号：US20030069445A1

  公开（公告）日：2003-04-10

  Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.

  本发明涉及生物试剂，其包括抑制β-淀粉样肽释放和/或其合成的化合物，因此在确定涉及β-淀粉样肽生成的细胞机制方面具有实用性。
• Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
  申请人：——

  公开号：US20030229024A1

  公开（公告）日：2003-12-11

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制&bgr;-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的用途。还公开了药物组合物，包括抑制&bgr;-淀粉样肽释放和/或合成的化合物，以及使用这样的药物组合物进行预防和治疗阿尔茨海默病的方法。
• REMEDY FOR EYE DISEASES ACCOMPANIED BY OPTIC NERVE INJURIES
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1666068A1

  公开（公告）日：2006-06-07

  An object of the present invention is to search for a novel medicinal use of a compound having a secretase inhibitory activity. Because the compound having a secretase inhibitory activity has a remarkable inhibitory effect on retinal neuronal cell death, it is useful as a therapeutic agent for a retinal disease typified by retinal vessel occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease or an eye disease accompanied by an optic neuropathy such as glaucoma.

  本发明的目的是寻找一种具有分泌酶抑制活性的化合物的新型药用用途。由于具有分泌酶抑制活性的化合物对视网膜神经细胞的死亡具有显著的抑制作用，因此它可作为一种治疗剂，用于治疗视网膜血管闭塞、糖尿病视网膜病变、缺血性视神经病变、黄斑变性、色素性视网膜炎和 Leber's 病等视网膜疾病或伴有视神经病变（如青光眼）的眼病。
• Galanthamine derivatives, methods for their obtaining and use
  申请人：Sopharma AD

  公开号：EP2123328B1

  公开（公告）日：2011-05-04